NUCLEAR MEDICINE & THERANOSTICS FOR MOLECULAR IMAGING & TARGETED THERAPY
Dr Aviral Singh,
Clinical Head of Theranostics and Nuclear Medicine, GenesisCare
Murdoch, Western Australia &
Consultant Nuclear Medicine Physician,
Fiona Stanley Hospital, South Metropolitan Health Service &
Royal Perth Hospital, Perth, Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | May 2026
Dr Aviral Singh is a globally renowned Nuclear Medicine Physician with special interest in Theranostics. He holds a Fellowship from the Royal Australasian College of Physicians (2024), specialist certificates in Nuclear Medicine and Radiation Protection from Germany (2019), an MSc in Nuclear Medicine from King’s College London (2005), and Doctor of Medicine and PG Diploma in Cardiology from Zaporozhye State Medical University, Ukraine.
Dr Singh is based in Perth, Western Australia since 2024 and serves as the Clinical Head of Theranostics and Nuclear Medicine at GenesisCare Australia. He is also a Consultant Nuclear Medicine Physician at Fiona Stanley and Royal Perth Hospitals, in addition to pursuing national and international consulting physician roles as Director at Infinity Theranostics.
His prior roles include fellowships at world-leading ENETS Centres of Excellence including, Zentralklinik Bad Berka, Germany and Royal North Shore Hospital, Australia, and consultant physician positions in nuclear medicine and theranostics in Australia, Germany, and UK, with leadership in clinical research and development, and additional training in intensive care and internal medicine.
Dr Singh has co-authored 50 peer-reviewed papers, contributed a book chapter on Copper-64 radiopharmaceuticals, and holds an h-index of 30. He has delivered over 40 invited lectures for prestigious clinical societies worldwide.
Dr. Singh acts as guest editor and associate editor and peer reviewer for multiple reputed nuclear medicine journals. He is an active researcher in the field of personalised nuclear oncology and is an Investigator for several Phase 1 to 4 clinical trials in the field of Theranostics.
Source: Supplied
-
Professor Kim Hemsley
RESEARCH IN SANFILIPPO SYNDROME, A EURODEGENERATIVE LYSOSOMAL STORAGE DISORDER THAT CAUSES CHILDHOOD DEMENTIA.
@ FLINDERS UNIVERSITY, SOUTH AUSTRALIA -
Investigating new approaches to target plaque inflammation in atherosclerosis
Associate Professor Peter Psaltis is an Academic Interventional Cardiologist who holds Level 2 NHMRC Career Development and National Heart Foundation Future Leader Fellowships. He has Faculty positions within the University of Adelaide, Central Adelaide Local Health Network (CALHN) and South Australian Health and Medical Research Institute (SAHMRI). Within SAHMRI, he is the Co-Theme Leader of the Lifelong Health, Program Leader of Heart and Vascular Health and Co-director of the Vascular Research Centre in the Lifelong Health Theme.
-
Impact of NextSense Institute Research in the field of sensory disabilities
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations. The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
